Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Well Corp (AMWL) vs Becton Dickinson and Co (BDX) Price & Performance

American Well Corp
Becton Dickinson and Co

Price performance

Price movement over the last 24 hours

Key statistics

American Well Corp vs Becton Dickinson and Co — how do they compare? American Well Corp trades at $9.7 (market cap $165.58M), while Becton Dickinson and Co trades at $151.94 (market cap $41.87B). The key difference: Becton Dickinson and Co is far larger — about 252.9× American Well Corp's market cap, and Becton Dickinson and Co pays a 2.76% dividend while American Well Corp pays none. Which is the better fit depends on your goals.

AMWLBDX
Market Cap
$165.58M$41.87B
Sector
HealthHealth
52-Week High
$9.91$185.39
52-Week Low
$3.78$135.49
Enterprise Value
-$9.66M$58.33B
Dividend Yield
2.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Well Corp

AMWL trades at $9.91, up 8.66% today, with bullish technical signals and positive momentum. The company shows improving financial trends with declining losses and strong gross margins of 52.9%, though it remains unprofitable with a -37.02% net margin. Recent news highlights Amazon's appointment of Amwell's co-founder to lead its healthcare unit, signaling industry validation.

While AMWL shows operational improvement and attractive valuation multiples (P/S 0.68, P/B 0.73), the stock faces headwinds from persistent losses and negative cash flow. Analyst consensus is cautious with a $7.25 price target below current levels, suggesting limited near-term upside despite recent positive momentum.

Becton Dickinson and Co

BDX trades at $151.94, up 0.72% on the day, with a bearish technical signal despite recent earnings beats. The stock is supported by consistent revenue growth, reaching $21.84B in 2025, and a forward P/E of 26.52. Analyst consensus is mixed with a $173.40 price target, and the company maintains a solid dividend, recently paying $1.05 per share. Cash flow trends show variability, with 2025 net cash flow negative $1.00B, though 2026 projects a positive $346M.

The outlook for BDX balances strong fundamentals against near-term headwinds. Revenue growth and strategic positioning in medical technology offer upside, but investor sentiment is cautious due to bearish technicals and margin pressures. Risks include hospital spending caution and competitive dynamics. The stock presents a hold case for long-term investors, with potential catalysts from continued earnings outperformance and innovation in healthcare technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Well Corp

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.

Read more on AMWL

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX